Previous Article | Next Article 
Molecular and Cellular Biology, July 2000, p. 5184-5195, Vol. 20, No. 14
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Docking Protein HEF1 Is an Apoptotic Mediator
at Focal Adhesion Sites
Susan F.
Law,
Geraldine M.
O'Neill,
Sarah J.
Fashena,
Margret B.
Einarson, and
Erica A.
Golemis*
Division of Basic Science, Fox Chase Cancer
Center, Philadelphia, Pennsylvania 19111
Received 3 December 1999/Returned for modification 17 January
2000/Accepted 10 April 2000
 |
ABSTRACT |
HEF1 (human enhancer of filamentation 1) is a member of a docking
protein family that includes p130Cas and Efs. Through
assembly of multiple protein interactions at focal adhesion sites,
these proteins activate signaling cascades in response to integrin
receptor binding of the extracellular matrix. The HEF1 protein is cell
cycle regulated, with full-length forms cleaved in mitosis at a caspase
consensus site to generate an amino-terminal 55-kDa form that localizes
to the mitotic spindle. The identification of a caspase cleavage site
in HEF1 led us to investigate whether HEF1 belongs to a select group of
caspase substrates cleaved in apoptosis to promote the
morphological changes characteristic of programmed cell death.
Significantly, inducing expression of HEF1 in MCF-7 or HeLa cells
causes extensive apoptosis, as assessed by multiple criteria.
Endogenous HEF1 is cleaved into 65- and 55-kDa fragments and a newly
detected 28-kDa form in response to the induction of apoptosis,
paralleling cleavage of poly(ADP-ribose) polymerase and focal adhesion
kinase (FAK); the death-promoting activity of over-expressed HEF1 is
associated with production of the 28-kDa form. While the generation of
the cleaved HEF1 forms is caspase dependent, the accumulation of HEF1
forms is further regulated by the proteasome, as the proteasome
inhibitors
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinyl and lactacystin enhance their stability. Finally, the induction of HEF1
expression also increases Jun N-terminal protein kinase (JNK)
activation, and activated JNK colocalizes with HEF1, implicating this
pathway in HEF1 action. Based on these results, we propose that
dysregulation of HEF1 and its family members along with FAK may signal
the destruction of focal adhesion sites and regulate the onset of apoptosis.
 |
INTRODUCTION |
Apoptosis, or programmed cell death
(PCD), is critical in an array of processes as apparently diverse as
nervous system development (69), maturation of lymphoid
cells (74), and appropriate attachment of epithelial cells
(26), but all these processes are linked by the requirement
of eliminating defined cellular populations in specific circumstances.
Apoptosis can be triggered by extracellular signals such as stimulation
of the tumor necrosis factor (TNF) and Fas families of death receptors
(3), surface immunoglobulin cross-linking (81),
or interference with cellular adhesion to substrate (26), as
well as by intracellular perturbations such as changes in mitochondrial
permeability (32) or activation of cell damage-sensing
pathways (25). A hallmark of apoptosis is the
activation of a cascade of cellular proteases, termed caspases, that
cleave proteins after aspartic acid residues found in an appropriate
amino acid context. Initiator caspases (caspases 8, 10, and others) at
the top of the cascade are activated and then sequentially cleave and
activate downstream effector caspases (e.g., caspases 3 and 7), which
in turn cleave a specific subset of cellular proteins. Cleavage of this
subset leads to characteristic changes in cell morphology, including
nuclear fragmentation and cytoskeletal rearrangement (55,
80), and ultimately results in production of apoptotic
bodies that are engulfed by surrounding cells (41). Because
of the central role of apoptosis in many biological processes,
it has been of considerable interest to elucidate the steps of these
morphological rearrangements and to understand the relation between
morphological controls in moribund versus normally growing cells.
It has long been noted that apoptosis and mitosis both require
similar programmed changes in cell shape and some conserved elements of
signaling (reviewed in reference 42). The first step
in both processes requires cell rounding and a reduction in cell
attachment to the extracellular matrix (ECM) through modulation of the
cell cytoskeleton. Subsequent changes in nuclear morphology, including
breakdown of the nuclear envelope and hypercondensation of the
chromatin (48), allow the packaging of nuclear fragments into apoptotic bodies or, in the case of mitosis, formation of the mitotic spindle. Although caspases were originally defined as
proteins specifically active in apoptosis, recent work has identified additional roles for these proteins in nonapoptotic cells (e.g., see reference 30). For example, caspase
3 activity has been shown to increase upon NIH 3T3 cell spreading;
reciprocally, cell spreading is blocked by the general caspase
inhibitor z-Asp (86). Two pieces of evidence specifically
link caspase activity and cell proliferation. First, a significant
transient increase in caspase 3 activity is detected in peripheral T
lymphocytes upon T-cell activation, when these cells are actively
proliferating but not engaged in apoptosis (60).
Second, survivin, a protein which has the ability to inactivate
caspases 3 and 7, is upregulated at the G2/M transition and
localizes to the mitotic spindle. Expression of survivin can block
taxol-induced apoptosis, suggesting that survivin may act to
inhibit a constitutive apoptotic signal in mitosis
(53). Thus, modulated caspase activity towards specific cellular targets may be important for normal cytoskeletal organization and cell cycle progression, while a dramatic increase or dysregulation of caspase activity is necessary to promote apoptosis.
HEF1 (human enhancer of filamentation 1) was first isolated in a screen
for human proteins with the ability to alter Saccharomyces cerevisiae morphology from round to filamentous hyperpolarized cells (45). HEF1 belongs to a larger family of docking
adapter proteins including p130Cas and Efs (also known as
Sin) (1, 38, 71) termed the Cas family. All members of this
family contain multiple protein-protein interaction domains, allowing
for the recruitment of additional proteins into a complex that
activates signaling cascades following cell adhesion (1, 38, 45,
57, 59, 63, 71, 84). These interaction domains include an
amino-terminal SH3 domain that binds polyproline-containing proteins, a
substrate domain with multiple tyrosines that when phosphorylated
recruit SH2-containing proteins, and a conserved carboxy-terminal
domain that may contribute to dimerization of Cas family members
(45, 46). In interphase cells, HEF1 and other Cas proteins
localize to sites of focal adhesion, bind to focal adhesion kinase
(FAK) through the conserved SH3 domain (45), and are
phosphorylated by FAK and Src family kinases in response to integrin
receptor binding of the ECM. This phosphorylation in turn activates SH2
binding sites to recruit the adapter protein Crk, which then stimulates
the Ras/Raf/Jun N-terminal protein kinase (JNK) signaling cascade
(4, 6, 24, 45, 57, 59, 66, 73, 77; reviewed in
reference 67), contributing to the promotion of cell
migration (16, 19, 43, 64; S. J. Fashena,
M. B. Einarson, G. M. O'Neill, and E. A. Golemis,
unpublished data).
In contrast to p130Cas, the HEF1 protein is regulated at
multiple levels in a cell cycle-dependent manner (47), with
regulation including changes in steady-state levels, phosphorylation
status, and proteolytic processing. As cells traverse through S phase and G2, full-length forms of HEF1 (p105 and p115)
accumulate at focal adhesion sites. Strikingly, at the G2/M
transition the full-length forms of HEF1 are cleaved at a caspase
consensus site to generate an amino-terminal HEF1 form,
p55HEF1, which localizes to the mitotic spindle, while
carboxy-terminal species are apparently degraded. The cleavage and
relocation of HEF1 during mitosis suggest that HEF1 may play a role in
coordinating attachment-based signals generated at focal adhesion sites
with cell cycle events in the nucleus, thereby promoting the transition from flat substrate-attached interphase cells to rounded mitotic cells.
The apparent involvement of a caspase-like activity in the production
of p55HEF1 at mitosis therefore led us to investigate
whether HEF1 belonged to a select subset of caspase substrates cleaved
in apoptosis to promote the cytoskeletal changes characteristic
of PCD and whether misregulation of HEF1 might independently contribute
to the induction of apoptosis.
The breast adenocarcinoma cell line MCF-7 has been well characterized
both for the endogenous expression of HEF1 (47) and its
intrinsic ability to undergo apoptosis (7, 13),
making these cells suitable for studies of HEF1 biological activities. Here we show that overexpression of the HEF1 protein in MCF-7 cells
efficiently induces apoptosis, as assessed by promotion of
caspase activation and cleavage of canonical effector caspase targets.
HEF1 overexpression results in the activation of JNK kinases and is
accompanied by the colocalization of HEF1 and activated JNK at focal
adhesions. Induction of apoptosis either by HEF1 overexpression
or by treatment with TNF alpha (TNF-
) or other standard
proapoptotic agents, leads to cleavage of HEF1 into 65-, 55-, and 28-kDa forms by a caspase 3-like or caspase 7-like activity, in a
time period paralleling cleavage of effector caspase targets poly(ADP-ribose) polymerase (PARP) and FAK. p130Cas is also
cleaved to produce a 28-kDa species following HEF1 overexpression; comparison of HEF1 and p130Cas sequences facilitated
delineation of the likely shared caspase cleavage target site as a DDYD
motif that overlaps a previously defined site of phosphorylation by
FAK. In transient-transfection assays in which survival rates of cells
overexpressing the wild-type, DLVA mutant, p55, or p28 forms of HEF1
were compared, the HEF1 proapoptotic activity was found to
depend on the expression of the p28 carboxy-terminal region of the
protein. Finally, the various HEF1 cleavage products were found to be
subject to degradation via the proteasome; however, the degree of
proteasome-dependent cleavage differs in mitosis and apoptosis,
likely contributing to the differential abundance of the cleaved HEF1
species during the two processes. These results, together with
complementary findings in the literature, suggest a model in which
regulation of the forms and abundance of HEF1 family members signals
the destruction of focal adhesion sites and regulates onset of mitosis or apoptosis.
 |
MATERIALS AND METHODS |
Cell lines and materials.
MCF-7 human breast carcinoma cells
and HeLa human cervical carcinoma cells were cultured under standard
conditions. The murine B-cell lymphoma line WeHI 231, as well as
anti-immunoglobulin M (
-IgM) antibodies, was a generous gift from
Kerry Campbell (Fox Chase Cancer Center) and was maintained in a
solution containing Dulbecco's modified Eagle medium (DMEM), 10%
fetal calf serum, glutamine, penicillin, streptomycin, nonessential
amino acids, and
-mercaptoethanol (10 µM). The construction of
MCF-7 transfectants carrying either full-length HEF1 or the empty
vector under the control of a tetracycline-repressible operator will be
described elsewhere (Fashena et al., unpublished data). The cells used
in this study are from the HEF1.M1 cell line and the CM1 cell line. Antibodies used in this study include anti-p130Cas,
antigelsolin, anti-FAK, and antipaxillin antibodies from Transduction Laboratories (San Diego, Calif.); anti-PARP antibody from Calbiochem (La Jolla, Calif.); anti-phospho-JNK antibody from Promega (Madison, Wis.), anti-JNK antibody from PharMingen (San Diego, Calif.); rhodamine-conjugated goat anti-rabbit antibodies from Molecular Probes
(Eugene, Oreg.); and dichlorotriazinyl amino fluorescein-conjugated goat anti-mouse antibodies from Jackson Immunoresearch (West Grove, Pa.). Anti-HEF1-R1 (here denoted HEF1/1) antibodies were
previously described (47). Anti-p130Cas antibody
has been previously shown to cross-react with the HEF1 C terminus
(47) and is therefore referred to here as
anti-HEF1/anti-p130Cas antibody. Another HEF1-specific
antibody (anti-HEF1/2) was generated by injecting into rabbits the
peptide KESSLSASPAQDKR, conjugated to keyhole limpet hemocyanin.
TNF-
was purchased from R & D Laboratories. 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) was obtained from Sigma (St. Louis, Mo.). Colorimetric caspase 3 substrate, Ac-DEVD-pNA, was purchased from Calbiochem
and dissolved in dimethyl sulfoxide (DMSO) as 5 mM stock
solutions and stored at
20°C. The caspase inhibitor peptide
z-DEVD-fmk and the specific proteasome inhibitor lactacystin were
purchased from Calbiochem, while the proteasome inhibitors
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinyl (ALLN) and
N-acetyl-L-leucinyl-L-leucinyl-L-methioninal
(ALLM) were obtained from Sigma. Puromycin dihydrochloride and
tetracycline hydrochloride were from Sigma, while hygromycin B
was from Roche (Indianapolis, Ind.). LT2 transfection reagent was
purchased from Mirus (Madison, Wis.).
Expression constructs.
Construction of the pCDNA1/HEF1
construct has been previously described (47). C-terminally
Myc-His-tagged full-length HEF1 was constructed by PCR amplifying HEF1
with primers containing N-terminal EcoRI and C-terminal
KpnI restriction enzyme sites. The fragment was then ligated
into EcoRI/KpnI digested pCNA3.Myc/His. The mouse
p130Cas cDNA insert was isolated by EcoRI
digestion from pCMV5.p130Cas. The resulting fragment was religated into
EcoRI-digested pcDNA3, and clones containing inserts in the
correct orientation were determined by nucleotide sequencing.
Additional HEF1 cDNAs were cloned in-frame into the pEGFP-C4 vector
(Clontech, Palo Alto, Calif.), to create fusion peptides consisting of
green fluorescent protein (GFP) fused to the N terminus of the HEF1
peptide. The GFP fusion constructs include (i) pEGFP.HEF1, encoding the
complete wild-type HEF1 protein sequence; (ii) pEGFP.55, encoding the
N-terminal 363 amino acids (aa) of HEF1 corresponding to the 55-kDa
N-terminal peptide produced following caspase cleavage at the conserved
DLVD motif (aa 360 to 363); (iii) pEGFP.DLVA, encoding full-length HEF1
carrying a point mutation (D
A) in the caspase cleavage site that has
been previously described (47); and (iv) pEGFP.28, encoding
the C-terminal 205 aa of HEF1 corresponding to the predicted 28-kDa
HEF1 C-terminal peptide including DDYD (aa 627 to 630).
HEF1 expression and assay of cell growth.
Stable cell lines
containing the parental tetracycline-regulatable vector with or without
the full-length HEF1 cDNA were generated in MCF-7 cells (Fashena et
al., unpublished data). These were plated at a density of approximately
106 cells per 100-mm-diameter plate into fresh DMEM plus
10% fetal bovine serum in the absence of tetracycline and other
selective antibiotics (induced) or in the presence of 1 µg of
tetracycline per ml (uninduced). The viability of cells expressing HEF1
was assayed using the colorimetric MTT assay essentially as described previously (15). Approximately 104 cells were
plated in wells of a 96-well plate at the start of each assay, and six
replicates were plated per assay. Prior to solubilization of the
precipitate with DMSO, plates were centrifuged for 5 min at
800 × g to collect floating cells. The medium was then
carefully aspirated and the precipitate was dissolved as described
previously (15). Cell numbers were calculated by preparing a
standard curve of cell number versus absorbance at 560 nm. Results are
expressed as the average cell number of 12 replicates from two
independent experiments ± the standard error of the mean.
Assay of caspase activity.
Floating and attached cells were
combined and extracted in caspase assay buffer (50 mM HEPES [pH 7.4],
100 mM NaCl, 0.1%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfate [CHAPS],
10 mM dithiothreitol, 1 mM EDTA, and 10% glycerol). The protein
content of extracts was determined using the Bio-Rad (Hercules, Calif.)
protein assay as per the manufacturer's instructions. Caspase assays
were performed as previously described (23). Briefly, 100 µg of total protein extracts were incubated at room temperature in a
final volume of 200 µl with Ac-DEVD-pNA (250 µM final
concentration) and, where indicated, z-DEVD-fmk (0.5 µM final
concentration) in caspase assay buffer. Triplicate samples were
incubated at room temperature, and the release of the pNA product was monitored at 405 nm in a microtiter plate reader (Multiskan Plus; Labsystems, Helsinki, Finland). Initial readings were taken at
the start of the incubation (T0) and final
readings were taken at the completion of the reaction at 24 h
(T1). The change in absorbance over time was
determined by subtracting T0 from
T1 for each sample.
Induction of apoptosis.
MCF-7 cells were plated and
grown for 48 h, reaching a cell density of 70% prior to TNF-
addition. Medium was replaced with fresh medium supplemented with
TNF-
(100 ng/ml). TNF-
treatment of stable cell lines was carried
out by plating cells directly into fresh DMEM plus 10% fetal bovine
serum, with or without addition of tetracycline as indicated,
containing TNF-
(100 ng/ml). Cells floating in the medium were
collected by centrifugation (285 × g for 5 min) and
extracted in combination with attached cells at the time points
indicated, as described below. WeHI 231 cells were plated at a density
of 5 × 104 cells/ml and treated with 1 µg of
-IgM antibodies per ml in complete medium. Cells were collected by
centrifugation and lysed as stated below. Blockade of caspase 3 and 7 activation was accomplished by incubation with the cell-permeating
caspase inhibitor z-DEVD-fmk at a final concentration of 25 µM, 30 min prior to and continuing after the addition of TNF-
or
-IgM as
per the manufacturer's recommendations.
Proteasome inhibition.
The proteasome and calpain were
inhibited by the peptide ALLN and its structurally related but
less-potent analog ALLM (36). The specific proteasome
inhibitor lactacystin was also used for comparison (22). The
proteasome inhibitors ALLN and ALLM were added coincident with the
addition of TNF-
at a final concentration of 50 µM, while
lactacystin was added at a final concentration of 10 µM.
Proteasome inhibition in mitosis was accomplished as follows. MCF-7
cells were blocked in 2 mM thymidine as previously described
(
47). Cells were washed twice in DMEM and then released in
DMEM
plus 10% fetal bovine serum for 4 h. Then either a DMSO
control
or lactacystin at a final concentration of 50 µM was added
and
the cells were incubated for 5 h more. Mitotic cells were then
harvested by gently tapping the dish and collecting cells in the
supernatant by
centrifugation.
Transient transfections and counting of GFP-positive cells.
HeLa cells were plated 24 h prior to transfection. Transfection
was accomplished using the LT2 reagent (Mirus) following the manufacturer's suggested protocol. Cells for Western blot analysis were harvested 24 h following the initiation of the transfection. For counting of GFP-positive cells, HeLa cells were plated 24 h
prior to transfection on coverslips. At 24 h posttransfection cells were fixed with 4% paraformaldehyde. Each cDNA construct was
transfected in triplicate. Eight random fields were then scored under
the 20× objective of a Nikon Eclipse E800 microscope for GFP-positive
cells. Each cDNA construct was transfected in triplicate, and the
experiment was repeated on three separate occasions. The percentage of
GFP-positive cells was determined by dividing the total number of
GFP-positive cells in eight fields by the average of three
determinations for the GFP vector alone, and the results were
multiplied by 100. Data shown consist of the average of nine replicates
from three separate experiments for each construct ± the standard
error of the mean.
Preparation of cell lysates and Western blot analysis.
Lysates were made as previously described (45, 47) in A-PTY
buffer (50 mM HEPES [pH 7.5], 50 mM NaCl, 5 mM EDTA, 1% Triton X-100, 50 mM NaF, 10 mM Na4P2O7),
supplemented with 1 mM phenylmethylsulfonyl fluoride, aprotinin (0.01 mg/ml), leupeptin (0.01 mg/ml), and 1 mM
Na3VO4. For adherent cultures, floating cells
were pooled with the adherent cells prior to lysis. The cell pellet was
then lysed in combination with lysates from the attached cells. Western analysis was carried out with the previously described antibody concentrations or those suggested by the manufacturer. Detection was
performed via chemiluminescence as described elsewhere (45).
Immunofluorescence.
MCF-7 cells were transfected with the
indicated constructs and 24 h posttransfection were fixed with 4%
paraformaldehyde and permeabilized with 0.2% Triton X-100. Following
incubation with primary antibody for 1 h, bound antibodies were
detected with either rhodamine-conjugated goat anti-rabbit or
dichlorotriazinyl amino fluorescein-conjugated goat anti-mouse
secondary antibodies. Cells were examined and confocal microscopy
performed using a Bio-Rad 600 laser scanning confocal microscope.
 |
RESULTS |
Induction of HEF1 expression promotes apoptosis, while
cleavage of endogenous HEF1 occurs following proapoptotic
stimuli.
Endogenous HEF1 exists during interphase as full-length
105-kDa and hyperphosphorylated 115-kDa forms, localized primarily at
focal adhesion sites. These endogenous full-length forms are cleaved
during mitosis, generating a 55-kDa amino-terminal form that localizes
to the mitotic spindle (47), while the carboxy-terminal end
of the protein is apparently degraded. We have also shown that HEF1
transiently transfected into HeLa cells is cleaved in a non-cell
cycle-regulated manner at a predicted caspase 3-like or caspase 7-like
(DLVD) consensus site, producing a 55-kDa amino-terminal peptide
comparable in size to the mitotic p55 species (47) and a
65-kDa carboxy-terminal peptide. These results raised the possibility that the overexpressed HEF1 protein might itself be activating the
caspase function and/or promoting apoptosis. If so, this
suggests that perturbation of HEF1-dependent signaling was a novel
initiator of the cell death machinery.
We have recently prepared MCF-7 cell lines stably expressing HEF1 or
the parental vector under the control of a tetracycline-regulatable
promoter (Fashena et al., unpublished data). To explore the role
of
HEF1 in apoptosis, we initially assayed whether the stable
cell
lines also showed signs of apoptosis upon HEF1 induction
and
whether the cleavage of HEF1 and canonical caspase substrates
is
concomitantly activated. At 48 h after induction of HEF1
expression,
the majority (70%) of cells round up, become refractile,
and float
off the plate, a behavior consistent with cell death (Fig.
1,
top). In contrast, uninduced cells and
vector control cells appear
normal, with the majority of cells being
adherent and proliferating
(Fig.
1, top, left-hand panel, and bottom).
At this time point,
the full-length HEF1 p105 and p115 species, as well
as the HEF1
p55-kDa cleavage product, are observed in induced HEF1
stable
lines but are not observed in either the uninduced
HEF1-containing
lines or vector controls, except for endogenous HEF1
(Fig.
2A).
To assess the viability of the
HEF1-expressing cells we next performed
an MTT cell viability assay on
cells induced to express HEF1 and
compared the results with those for
uninduced cells and vector
control cells in the presence and absence of
tetracycline. At
48 and 72 h after induction of HEF1 expression
there is a clear
loss of viability of the HEF1-expressing cells
compared with the
viability of the controls (Fig.
1B). We note that
floating cells
were collected by centrifugation prior to assaying
cleavage of
the MTT substrate, and therefore it is expected that the
total
number of viable cells represents both the floating and adherent
populations.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 1.
HEF1 expression causes cell death. (A) Cells were grown
for 48 h in the presence (uninduced) or absence (induced) of
tetracycline and, where indicated, TNF- and were examined by
phase-contrast microscopy. HEF1 stable transfectants (HEF1 cell line)
were compared with a negative control cell line (vector cell line). (B)
Cells were grown in the presence or absence of tetracycline, and cell
numbers were determined over a 72-h period using the MTT cell viability
assay. Circles indicate the HEF1 cell line and squares indicate the
vector control cell line grown in the presence (solid) or absence
(open) of tetracycline. Data points represent the average of six
replicates from two independent experiments. Error bars indicate the
standard errors of the mean.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
HEF1 expression causes protein cleavage and increased
caspase activity. (A) Lysates from a HEF1 cell line and a control
vector cell line were prepared from cells grown for 48 h under one
of the following conditions: induced, noninduced, or noninduced in the
presence of TNF- . Western blots of total cell lysates were probed
with antibodies to HEF1 ( -HEF1/1) and to PARP ( -PARP). (B)
HEF1-expressing cells and vector control cells were grown for 48 h
under inducing or noninducing conditions. Lysates were then incubated
with Ac-DEVD-pNA (250 µM) for 24 h. Formation of
product was monitored at 405 nm in the absence ( ) or presence (+) of
the caspase 3 inhibitory peptide z-DEVD-fmk (0.5 µM final
concentration) as indicated. Experiments were repeated at least three
times, and a representative experiment is shown. Error bars represent
the standard errors of triplicate samples.
|
|
Caspase induction is a specific indicator of apoptotic cell
death. To determine if caspases were being activated by HEF1
expression,
we assayed cleavage of the known caspase 3 substrate
(
8,
49)
and apoptosis marker, PARP, following HEF1
induction. As positive
controls for PARP cleavage we included uninduced
HEF1 cells and
vector control cells treated with TNF-

, a treatment
previously
shown to activate caspases and cause apoptosis in
MCF-7 cells
(
13). PARP cleavage was detected following
either TNF-

treatment
or HEF1 induction but not in the untreated and
uninduced HEF1
and vector control cells (Fig.
2A). Notably, TNF-

treatment resulted
in production of the 55-kDa HEF1 cleavage product
both in uninduced
HEF1-containing and vector control lines, suggesting
that endogenous
HEF1 was also cleaved. In addition, cells induced to
express HEF1
exhibited enhanced cleavage (approximately twofold) of the
colorimetric
caspase 3 substrate Ac-DEVD-
pNA in comparison
to control cells
(Fig.
2B). Further, activity towards the caspase 3 substrate in
the HEF1-expressing cells is potently blocked by the
inhibitory
peptide z-DEVD-fmk (Fig.
2B), confirming the specificity of
the
cleavage. These results indicated not only that HEF1 overexpression
does induce caspases but that one consequence of their activation
is
subsequent cleavage of endogenous HEF1. We note that, as the
MCF-7 cell
line has been described as deficient in caspase 3,
the detected
activity is likely to correspond to that of caspase
7 or one of the
other redundant caspases active in these cells
(
39).
If HEF1 is a significant natural target for cleavage by caspases in
apoptosis, then a time course of endogenous HEF1 cleavage
should parallel that observed for other defined cytoskeletal and
signaling proteins known to be cleaved following apoptotic
stimulus.
These include the HEF1 interactive partner FAK
(
87), the morphoregulatory
p21-associated kinase (PAK)
(
70), the actin-severing and/or
-capping protein gelsolin
(
44), and others (e.g., see references
9,
10,
12, and
58). We therefore examined the
timing
of endogenous HEF1 cleavage in response to TNF-

treatment in
parental MCF-7 cells. Approximately 16 h after TNF-

addition,
there is a decline in the 105- and 115-kDa full-length forms of
HEF1
and an accumulation of the 55-kDa amino-terminal peptide
(Fig.
3). For comparison, we also analyzed the
cleavage of the
caspase substrates FAK, PARP, and gelsolin. FAK and
PARP cleavage
coincide with the production of the 55-kDa HEF1 form,
whereas
gelsolin cleavage is detected approximately 4 h later
(Fig.
3A).
This suggested that HEF1 cleavage, like that of FAK and
PARP,
is an earlier event in the apoptotic process and may
occur prior
to dismantling of the cell cytoskeleton. The
cell-permeating caspase
3 inhibitory peptide z-DEVD-fmk inhibited
generation of p85 FAK,
p85 PARP, and the 55-kDa HEF1 form at both 15 and 24 h after TNF-
addition (Fig.
3B), confirming the caspase
dependence of the cleavage
events. Finally, HEF1 cleavage from full
length to p55 was observed
in an independent cell type, WeHI 231 B
cells, in which apoptosis
was induced by an entirely different
stimulus, antibody cross-linking
of surface IgM. This result indicated
that the caspase targeting
of HEF1 was not specific to MCF-7 cells and
TNF-

treatment (Fig.
3C). In sum, these results indicate that HEF1
expression in the
absence of other inducing agents can induce caspase
activation
and cause apoptosis in MCF-7 cells. Furthermore,
HEF1 cleavage
is an early downstream event following apoptotic
stimulation in
multiple cell types.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
Endogenous MCF-7 HEF1 is cleaved by a caspase 3-like
activity. (A) MCF-7 cells treated with TNF- (100 ng/ml). (B) MCF-7
cells treated with TNF- (100 ng/ml) in the presence (+) or absence
(--) of the caspase 3 inhibitory peptide z-DEVD-fmk at a final
concentration of 25 µM. (C) WEHI 231 cells were treated with -IgM
antibodies (1 µg/ml) and extracted at the indicated times. Total
proteins were extracted at the indicated time points, and Western blots
were probed with the antibodies ( ) indicated on the right.
|
|
Mechanistically, the fact that TNF-

and HEF1 induction both activate
caspases can be explained by hypothesizing that HEF1
overexpression
activates a pathway downstream of TNF-

, in which
case dual treatment
would not have greater effect than treatment
with either TNF-

or
HEF1 expression alone. Alternatively, HEF1
is activating a separate
pathway. To address this point, we determined
whether simultaneous
overexpression of HEF1 and TNF-

treatment
resulted in a more
pronounced effect than either stimulus independently.
On a gross
morphological level, treatment with TNF-

alone resulted
in a low
level of cell rounding and death; in contrast, HEF1 induction
together
with TNF-

treatment led to essentially 100% cell death
at 48 h
(Fig.
1, center panels). Cells were grown under inducing
and
noninducing conditions with and without the addition of TNF-
as
indicated, and cell lysates were prepared and analyzed for
HEF1 and
PARP cleavage at the indicated time points (Fig.
4).
There is an increase in the degree of
both HEF1 and PARP cleavage
in cells induced to express HEF1 and
treated with TNF-

. Control
uninduced cells treated with TNF-

displayed significantly less
PARP cleavage than induced cells and
induced cells receiving TNF-
treatment. This potentiation of cell
death indicates that HEF1
expression may either prime the TNF-

death
pathway or work synergistically
to facilitate apoptosis.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 4.
Cell death induced by HEF1 expression is potentiated by
TNF- treatment. HEF1 stable transfectants were grown under inducing
conditions, inducing conditions plus TNF- , and noninducing
conditions plus TNF- . Vector control cells were grown under inducing
conditions plus TNF- . Western blots were probed with antibodies to
HEF1 ( -HEF1/1) and to PARP ( -PARP).
|
|
HEF1 caspase cleavage products are differentially regulated by
proteasomal degradation in mitosis and apoptosis.
As
previously noted, a p65 HEF1 carboxy-terminal cleavage product was
readily identified following transient transfection of HEF1, a
condition now defined as inducing apoptosis, but was not
detectable in mitosis (47). To probe the significance of this difference, we searched for the appearance of
lower-molecular-weight HEF1-derived species over the time course for
which we had characterized appearance of p55 following TNF-
stimulation of apoptosis (Fig. 5). For this purpose, we used antibodies
that were specific for HEF1 at epitopes flanking the previously defined
DLVD cleavage site; to scrutinize the extreme carboxy-terminal region
of HEF1, it was necessary to use antibodies that cross-reacted with
both HEF1 and p130Cas, as antibodies specific for HEF1 are
unavailable for this region. Concurrently, we assayed for production of
the 65-kDa carboxy-terminal peptide; however, there was very little
detectable p65 observed. This is possibly due to the unstable nature of
this peptide (47; also see below). Unexpectedly,
during this analysis we noted the appearance of an additional
immunoreactive protein with an estimated molecular mass of 28 kDa. The
generation of this form begins at 12 h following TNF-
treatment
of MCF-7 cells (Fig. 5A), paralleling the induction of the 55-kDa
species (Fig. 2 and 3), and is inhibited by treatment with z-DEVD-fmk
(Fig. 5B).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
A 28-kDa caspase cleavage product is generated from both
HEF1 and p130Cas. (A) MCF-7 cells were treated with TNF-
(100 ng/ml), and total protein lysates were probed with
anti-HEF1-p130Cas antibody ( -HEF1/p130Cas).
(B) MCF-7 cells were treated with TNF- (100 ng/ml) in the presence
(+) or absence (--) of the caspase 3 inhibitory peptide
z-DEVD-fmk at a final concentration of 25 µM. Western blots were
probed with -HEF1/p130Cas. (C) HeLa cells were
transfected with the empty vector (V), HEF1 (H), HEF1
carboxy-terminally tagged with the Myc epitope (H-M), or
p130Cas (p130). Western blots were probed with
-HEF1/p130Cas. (D) Diagram of the HEF1 caspase cleavage
sites and the pieces that are generated.
|
|
Bannerman et al. (
5) have recently reported that
p130
Cas is cleaved in response to lipopolysaccharide
treatment of epithelial
cells (a proapoptotic stimulus),
generating a 28-kDa p130
Cas peptide. Since MCF-7 cells
express both p130
Cas and HEF1 and both proteins contain the
anti-p130
Cas antibody epitope in their C termini, the
observed p28 species
may have been derived from either protein. To
determine the origin
of the p28 species, full-length HEF1 was
carboxy-terminally tagged
with the Myc epitope [HEF1-Myc (H-M)],
transfected into HeLa cells
and compared with full-length HEF1 (H),
p130
Cas (p130), or the empty vector (V) similarly
transfected. Lysates
from HEF1-Myc-transfected cells have two
anti-p130
Cas immunoreactive bands (Fig.
5C). One band
migrates at the same
rate as the 28-kDa protein observed in the HEF1-
and p130
Cas-transfected cells and represents cleaved
endogenous HEF1 and/or
p130
Cas. In contrast, the second
band has a comparatively retarded electrophoretic
mobility and
corresponds to the 28-kDa carboxy-terminal domain
of HEF1 fused to the
Myc tag. These data indicate that at least
some of the 28-kDa form
observed in MCF-7 cells is likely to be
derived from HEF1. Based on
predicted molecular masses, potential
caspase sites shared between HEF1
and p130
Cas, and the location of the
anti-p130
Cas antibody epitope, a conserved DDYD (aa 627 to
630) motif is the
only apparent candidate cleavage site (shown in Fig.
5D); further,
a construct made to express the predicted p28
(HEF1
630-834)
comigrated with the observed p28 endogenous
band (data not shown).
We note that, although examination of a
DDYD

DDYA mutant would
bear on this issue, it is experimentally
difficult to evaluate
such a mutant, as modulation of the DDYD site
destroys the ability
of the HEF1/p130
Cas antibody to
recognize the protein, while appending a carboxy-terminal
tag to the
expressed p28 form of HEF1 results in other changes
that make
interpretation difficult (results not
shown).
The above results indicate that caspases are required for processing of
HEF1 to three distinct forms in apoptosis (p55, p65,
and p28)
but do not address the differences in abundance of the
derivative
species in apoptotic and mitotic cells. We therefore
investigated the possibility that levels of HEF1-derived peptides
might
additionally be regulated by proteasomal processing, as
activity of the
proteasome has been shown to be closely tied to
caspase function
(reviewed in reference
68). Addition of the
calpain
and proteasome inhibitor ALLN to MCF-7 cells treated with
TNF-

led
to a substantial increase in observed levels of the
65-, 55-, and
28-kDa forms of HEF1, indicating that although these
forms accumulate
to levels higher than those detected in normally
dividing MCF-7 cells
following TNF-

treatment, they are nevertheless
being actively
degraded (Fig.
6A). Similar results were
obtained
with a less-potent analog of ALLN, ALLM, as well as the
specific
proteasome inhibitor lactacystin (data not shown). In
contrast,
in a synchronized population of mitotic MCF-7 cells, the
addition
of lactacystin induced a marked increase in the 65- and 28-kDa
HEF1 forms compared to untreated cells, while the amount of the
55-kDa
form remained unchanged (Fig.
6B). These results indicate,
firstly,
that the abundance of the HEF1 forms is controlled not
only by caspases
but also through degradation via the proteasome
and, secondly, that the
p55 form is subject to proteasomal degradation
during
apoptosis, but not mitosis.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 6.
The stability of HEF1 and its cleavage products (65, 55, and 28 kDa) is regulated by the proteasome. (A) MCF-7 cells were
treated with TNF- in the absence (--) or presence (+) of the
proteasome inhibitor ALLN. Lysates were probed with anti-HEF1
antibodies (anti-HEF1/1 antibody [ -HEF1/1] to detect p115, p105,
and p55; anti-HEF1/2 antibody to detect p65) or
anti-HEF1/p130Cas antibody to detect the 28-kDa species.
HeLa cells transfected with the HEF1 cDNA were run in the right lane as
a size control for the various HEF1 cleavage products. (B) MCF-7 cells
were synchronized by thymidine block. The cells were released for
4 h prior to the addition of the proteasome inhibitor lactacystin
(final concentration, 10 µM). Mitotic cells were collected at 9 h by mitotic shake off, and lysates were probed with either
anti-HEF1/p130Cas antibodies to detect the 65- and 28-kDa
forms or anti-HEF1 antibodies to detect the 55-kDa form.
|
|
The C-terminal 28-kDa HEF1 peptide is sufficient to induce cell
death.
The preceding results indicate that the relative abundance
of HEF1 forms is subject to complex regulation, suggesting that processed versus full-length forms of the molecule might possess discrete activities in apoptosis. Therefore, to further assess the role of the full-length versus processed HEF1 versions, we created
GFP fusion constructs that correlate to wild-type HEF1, the 55-kDa HEF1
N-terminal fragment, a mutant of HEF1 (DLVD
DLVA) that cannot be
cleaved to produce p55 and p65 cleaved forms, and the 28-kDa HEF1
C-terminal fragment (Fig. 7A). Modeling on protocols in which the
ability of transiently expressed peptides to induce apoptosis
is assessed by counting beta-galactosidase-positive (that is,
transfected) cells (e.g., see reference 33), HeLa cells were transiently transfected and GFP-positive cells were scored
to determine the effect of expressing HEF1 and the relevant panel of
HEF1-derivatives on cell survival. The number of GFP-positive cells for
each construct is expressed as a percentage of positive cells
transfected with the pEGFP vector control (Fig.
7B). We note that transfected GFP.HEF1
localizes to focal adhesions (see Fig. 8B) and also undergoes cleavage,
producing a GFP-fused 55-kDa N-terminal peptide (Fig. 7C), suggesting
that the fusion proteins are behaving similarly to the native proteins
with respect to at least two important criteria.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
The 28-kDa HEF1 caspase cleavage product causes cell
death. (A) Diagrammatic representation of GFP fusion constructs
corresponding to wild-type HEF1 (GFP.HEF1), the 55-kDa N-terminal
peptide (GFP.55), the full-length HEF1 molecule containing a mutation
in the caspase cleavage site that prevents production of the 55-kDa
N-terminal peptide (GFP.DLVA), and the 28-kDa C-terminal peptide
(GFP.28). (B) HeLa cells and MCF-7 cells (inset) were transiently
transfected with the GFP fusion constructs, and GFP-positive cells were
scored as outlined in Materials and Methods. Total numbers of
GFP-positive cells are expressed as a percentages of the number of
control cells transfected with the GFP vector alone. Data represent the
average of nine replicates from three independent experiments. Error
bars indicated the standard errors of the mean. (C) Total proteins were
extracted from HeLa cells transfected with GFP.DLVA, GFP.HEF1, and
pCDNA.HEF1, and Western blots were probed with the indicated antibodies
( prefix).
|
|
As expected from the results described above, transfection of the
GFP.HEF1 construct resulted in a reduced yield of GFP-positive
cells
relative to transfection of the GFP vector (Fig.
7B). The
GFP.55
construct produced significantly more transfectants than
the GFP.HEF1
construct. Conversely, the percentage of GFP.DLVA-positive
cells was at
a level similar to that of the GFP.HEF1 transfectants.
The DLVA
construct does not undergo cleavage to produce the 55-kDa
N-terminal
peptide (
47) (Fig.
7C), although the downstream DDYD
cleavage site remains intact, theoretically allowing p28 production.
Further analysis demonstrated that a protein band corresponding
in size
and antibody reactivity to the HEF1 28-kDa C-terminal
peptide could be
detected in lysates extracted from cells transfected
with the GFP.DLVA
construct (Fig.
7C), although available antisera
do not exclude the
possibility that this form results from cleavage
of p130
Cas
(as in Fig.
5C). These results suggest either that the full-length
HEF1
protein is proapoptotic or that a proapoptotic moiety
residing
in the C terminus is produced from the DLVA mutant. In
agreement
with the latter possibility, transfection with the GFP.28
construct
also results in a low percentage of GFP-positive cells.
Finally,
to demonstrate that this result is not specific to HeLa cells,
we repeated assays with the GFP, GFP.HEF1, and GFP.28 constructs
in
MCF-7 cells. By 24 h after transfection, the frequency of cells
expressing GFP.HEF1 is reduced twofold relative to that of cells
expressing GFP, while cells expressing GFP.28 are found at less
than
10% of control levels, supporting the idea that this domain
independently and potently induces cell death (Fig.
7B,
inset).
HEF1 induces activation of JNK signaling.
Recent studies have
indicated that the HEF1 family member p130Cas associates
with the adapter protein Crk to couple extracellular stimuli to
activation of the JNK pathway (6, 24). In light of the
previously reported association between HEF1 and Crk (57, 59) and the putative role for JNKs in apoptosis (reviewed
in reference 37), JNK phosphorylation in HEF1 stable
cell lines was examined using antibodies that specifically recognize
phosphorylated JNK1 and JNK2, following the observation that activation
requires and is reflected by phosphorylation of JNKs on amino acids
T183 and Y185 (21). Full-length 105- and 115-kDa HEF1 is
abundant by 6 h after induction, with the accumulation of the p65,
p55, and p28 cleavage products first noticeable at 9 to 12 h (Fig. 8A). JNK1 and JNK2 are phosphorylated and
activated around 16 h after induction of HEF1 expression (Fig.
8A), but not in the uninduced HEF1 cell lines or in vector-expressing
control cell lines (data not shown). As a control, Western blots of
cell lysates were probed with antibodies to JNK, demonstrating that
there are approximately equivalent total JNK levels in all of the cell
extracts (Fig. 8A).


View larger version (70K):
[in this window]
[in a new window]
|
FIG. 8.
HEF1 overexpression causes increased phospho-JNK levels.
(A) HEF1 cells were induced for HEF1 expression, and total proteins
were extracted at the times indicated. Western blots of total proteins
were probed with antibodies to HEF1 ( -HEF1/1 and
-HEF1/p130Cas) or anti-phospho-JNK antibodies
( -phospho-JNK), and to indicate equivalent loadings of total
proteins, blots were then probed with antibodies to JNK ( -JNK). (B)
Phospho-JNK localizes to focal adhesions and colocalizes with the HEF1.
Shown are merged confocal images of MCF-7 cells transfected with the
GFP vector alone (panel A) or GFP.HEF1 (panel B). Immunofluorescence
was performed with phospho-specific anti-JNK antibodies. GFP is shown
in green, and phospho-JNK staining is shown in red; yellow represents
merged red and green staining.
|
|
Recent reports have noted that activation of regulatory kinases such as
MEK kinase 1 and JNK is accompanied by changes in
intracellular
localization (
20,
62). Analysis of untransfected
MCF-7 cells
or MCF-7 cells transfected with GFP indicates that
the population of
activated JNK in these cells localizes to focal
adhesions, based on
colocalization with focal adhesion markers
such as paxillin (Fig.
8B
and results not shown). Following the
observation that the levels of
phospho-JNK increase after HEF1
expression, we examined subcellular
expression of phospho-JNK
in GFP.HEF1-transfected MCF-7 cells.
Consistent with the idea
that the activation of JNK might be linked
with proximity to HEF1,
immunofluorescent analysis using the
phosphorylation-specific
anti-JNK antibody demonstrated extensive
colocalization of GFP.HEF1
and phosphorylated JNK (Fig.
8B), suggesting
that the observed
activation may proceed via the combined function of
proteins complexed
at focal adhesions. The observation that formation
of the HEF1
cleavage products appears to precede JNK phosphorylation
and/or
activation suggests that these cleavage events may be associated
with JNK activation; alternatively, the activation may be due
to the
sustained overexpression of the full-length form of
HEF1.
 |
DISCUSSION |
In epithelial cells, the decision to remain quiescent,
proliferate, or undergo apoptosis is influenced by positional
information such as cell-cell contacts and attachment status. Proteins
associated with cell attachment structures may transmit such growth or
death stimuli, as they are well positioned to integrate extracellular physical constraints with intracellular signaling cascades. Cas family
proteins are important targets of integrin-mediated attachment signals
(reviewed in reference 67). While other studies have focused on roles for p130Cas and HEF1 in control of cell
motility (16, 19, 43, 64; Fashena et al.,
unpublished data), we have found that the HEF1 protein is dynamically
regulated during the cell cycle, with specific caspase cleavage
converting a focal adhesion-associated assembly factor to a truncated
form associated with mitotic spindles. This has lead to the hypothesis
that changes in HEF1 expression and localization might play important
roles in controlling cell attachment and cell cycle progression
(45, 47) and potentially cell viability.
Results here provide the first demonstration that HEF1 and
p130Cas may additionally play an important role in active
induction of apoptosis. The primary findings reported herein
supporting this view are first, significantly, that HEF1 overexpression
triggers caspase activation and apoptosis in MCF-7 breast
carcinoma cells and HeLa cervical carcinoma cells; further, HEF1
overexpression-initiated apoptosis is augmented by TNF-
treatment. Second, we find that the endogenous HEF1 protein is a target
of cleavage in apoptosis, with a caspase 3-like activity
cleaving the protein into 55-, 65-, and 28-kDa peptides. Third, these
cleavages occur relatively early following the initiation of
apoptosis, paralleling cleavage of FAK and PARP and preceding
that of gelsolin. Fourth, the abundance of the HEF1 cleavage species is
additionally controlled by proteasome-mediated degradation. Fifth,
structure-function analysis suggests that at least one potent
proapoptotic activity resides in the conserved carboxy-terminal
region of HEF1. Finally, the conversion of overexpressed HEF1 to
caspase-cleaved fragments is followed by the induction of JNK
phosphorylation, while HEF1 and activated populations of JNK colocalize
at focal adhesions.
Effector caspases have been described as inducing the cleavage of many
classes of proteins during apoptosis. These include nuclear
proteins involved in DNA surveillance and repair (PARP [49] and DNA-dependent protein kinase [34,
76]), nuclear structure (nuclear lamins [50,
78]), and other diverse functions (U1 snRNP [17,
79], sterol response element binding proteins 1 and 2 [85], huntingtin protein [31], D4 GDP
dissociation inhibitor [61], p21 [Cip1/Waf1]
[29], and pRb [2, 40]). The majority
of cytoplasmic proteins cleaved by caspases are involved in regulating
cytoskeletal organization, and include FAK (87), gelsolin
(44), PAK (70), Gas2 (9), fodrin
(58), and several adherens junction proteins (e.g.,
-catenin and adenomatous polyposis coli [10, 12]).
Cleavage of target proteins by effector caspases may generate protein
fragments that have altered activity which actively promotes
apoptosis. PARP, as an example, has a complex role, as its
cleavage is thought to prevent depletion of ATP and NAD (important for
the later stages of apoptosis) and inhibit the DNA repair
mechanism allowing double-stranded breaks in the DNA to accumulate
(8, 75). FAK cleavage generates a form that localizes to
focal adhesion sites but does not contain the kinase domain and acts as
a dominant negative (28). In contrast, gelsolin and PAK
become activated by caspase cleavage, with cleavage stimulating
gelsolin-dependent cleavage of actin filaments (44) and PAK
kinase acquiring enhanced activity toward its substrates (51,
70). In both cases, activation results in changes in the actin
cytoskeleton and induction of apoptosis; to date, the degree to
which the morphological changes and proapoptotic effect are
interdependent remains to be determined.
Our data suggest that the cleavage products of HEF1 are not all simply
inactivated forms of the full-length protein but that they possess
independent activities. In mitosis, the p55HEF1 species is
relatively stable and exhibits a localization pattern distinct from
that of the full-length form, suggesting a separate function which may
embody action as a sentinel for focal adhesion disassembly and
readiness for cytokinesis (47). In contrast, the p28 and p65
forms of HEF1 are virtually undetectable due to proteasomal
degradation, suggesting either that their clearance is necessary or
that they are functionally mute. In contrast, all forms of the protein
are present in apoptotic cells, and hence available to play an
active role in the apoptotic process; our results suggest that
p28HEF1 function may be particularly relevant in the
promotion of apoptosis.
Although Cas family members have been shown to induce motility, no
previous report has noted a role for these proteins in apoptotic progression. One possible reason for this difference is that the ability of these proteins to induce apoptosis is
restricted by cell type; other studies have focused on Cas protein
overexpression in fibroblasts and lymphoid cells. However, we note in
this study that the ability of HEF1 to induce apoptosis is not
restricted to MCF-7 cells, as comparable results are obtained in HeLa
cells (Fig. 7 and results not shown). Alternatively, given that other studies were performed by transient transfection or by creation of
stable lines constitutively expressing the Cas family proteins, it may
be that the apoptotic effect was more difficult to discern. Our
data suggest that p130Cas may have a similar potential to
induce apoptosis in epithelial cells in that transfection of a
construct expressing p130Cas resulted in the generation of
a p28 species (Fig. 5C), most likely due to caspase-mediated cleavage,
hence reflecting caspase activation. Finally, it has been noted the
HEF1 protein is highly expressed in T and B cells (57, 59,
65). Given the discrete requirements for adherence in cell growth
of lymphoid cells, it will be of interest to examine whether variation
of HEF1 and/or p130Cas expression affects viability of
these populations.
One key question raised by this study is whether the promotion of
apoptosis by HEF1 is direct or indirect. Potential indirect mechanisms of HEF1 action in apoptosis might include changes in the cytoskeleton following HEF1 expression that impose physical stress
on cells (Fashena et al., unpublished data) and/or inappropriate activation of signaling cascades via HEF1-dependent alteration of focal
adhesion complexes. In this context, the similar timings of FAK and
HEF1 cleavage are intriguing, given the previously described
interactions between the two proteins in which FAK binding and
phosphorylation of HEF1 in response to integrin receptor ligation allow
the recruitment and activation of various signaling molecules (reviewed
in reference 67). FAK has been implicated as a
sensor of epithelial cell attachment, based on the observations that constitutively active FAK blocks apoptosis induced by cell
detachment (anoikis) (27), whereas inhibition of FAK
expression in cultured fibroblasts can promote apoptosis
(35). This suggests that one role of endogenous HEF1 and FAK
cleavage may be to block survival signals initiated by cell attachment.
We note that our observations of HEF1 induction of apoptosis by
overexpression, may appear contradictory when compared with cleavage
and degradation of the endogenous molecule by proapoptotic
stimuli. However, the overexpression results may be explained by posing
a model in which levels of HEF1, FAK, and associated proteins at focal
adhesions are carefully balanced. Inappropriate expression of
individual constituents of focal complexes (such as HEF1) might
additionally interfere with adhesion-related survival signaling.
Finally, our data suggest that HEF1 and p130Cas are
similarly cleaved at a conserved DDYD motif that demarcates the
carboxy-terminal region to produce the p28 species. Intriguingly, this
site overlaps with the site of FAK phosphorylation and subsequent Src
family kinase binding in Cas proteins (77), raising the possibility that the susceptibility of HEF1 and p130Cas to
cleavage may be governed by phosphorylation and the degree of
association with focal adhesions.
Enhancement of JNK activity has also been implicated as a contributor
to apoptosis in a number of studies, although the mechanism of
JNK involvement in the process is not yet completely clear and may be
cell type and stimulus dependent (18, 52, 54). In our
examination of JNK signaling in relation to HEF1 induction, the
proximity of HEF1 and phospho-JNK at sites of focal adhesion, along
with the observed increases in phospho-JNK expression following HEF1
expression, is particularly interesting given recent reports of the Nsp
proteins (Nsp1 to Nsp3 [56]) and the orthologous Cas-HEF1-associated signal transducer (CHAT) (Nsp3) protein. These proteins have been defined as molecules that activate JNK signaling in
response to integrin-ECM contact. CHAT has been shown to interact with
HEF1 and p130Cas through their carboxy-terminal conserved
domains (corresponding to the region encompassed in p28) and is
proposed to contribute to the activation of JNK signaling
(72). Intriguingly, and indirectly supporting the functional
interrelatedness of Nsp and Cas proteins, a retroviral integration
screen designed to identify genes whose function was related to
estrogen resistance and development of breast cancer turned up a small
number of positive candidate loci, of which BCAR1, BCAR2, and BCAR3
have so far been defined. Strikingly, BCAR1 has been shown to be
p130Cas (11, 83), while BCAR3 is Nsp2
(82). In sum, these results suggest a model in which the
action of the HEF1 carboxy terminus as a docking site for Nsp and CHAT
proteins enables activation of JNK kinases. Given that enhanced JNK
activation occurs at later stages following HEF1 induction, it may be
that the activation event is dependent upon the release of particular
truncated forms, such as p28, in signaling dependent on Nsp and CHAT.
Notably, the initiator kinase for the JNK signaling pathway, MEK kinase 1, is itself activated by caspase cleavage in anoikis (14). Alternatively, previous work with p130Cas has shown that
this protein can activate the JNK pathway through its recruitment of
Crk (6, 24, 57, 59), indicating that sequences in the SH2
binding site region (substrate domain) of HEF1 may separately
contribute to activation. The importance of HEF1-stimulated JNK
activity awaits further experimentation and clarification of the role
that JNK activation plays in apoptosis.
In summary, the Cas family members have been implicated in an
increasingly diverse set of physiological processes (67), including control of cell attachment, T-cell costimulation, migration, cell cycle, transformation, and now apoptosis. The selective
proteolytic processing and relocalization of HEF1 during
apoptosis and mitosis detailed here provide an economical and
elegant means of extending the function of a single protein to
different biological spheres.
 |
ACKNOWLEDGMENTS |
S.F.L. and G.M.O. contributed equally to this study.
We are grateful to Maureen Murphy and Kerry Campbell for helpful
discussions, critiques, and the gift of reagents. We thank Maureen
Murphy and Mary Ann Sells for thorough review of the manuscript.
E.A.G. was supported in this work by NIH grant RO1 CA63366 and core
funds CA-06927 (to Fox Chase Cancer Center). S.F.L. was supported by
American Cancer Society fellowship PF-4383 and NIH fellowship F32
GM18223. G.M.O. was supported by a W. J. Avery Fellowship. S.J.F.
was supported by NIH postdoctoral training grant T32 CA09035.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Fox Chase Cancer
Center, 7701 Burholme Ave., Philadelphia, PA 19111. Phone: (215)
728-2860. Fax: (215) 728-3616. E-mail:
EA_Golemis{at}fccc.edu.
 |
REFERENCES |
| 1.
|
Alexandropoulos, K., and D. Baltimore.
1996.
Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel, p130Cas-related protein, Sin.
Genes Dev.
10:1341-1355[Abstract/Free Full Text].
|
| 2.
|
An, B., and Q. P. Dou.
1996.
Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate.
Cancer Res.
56:438-442[Abstract/Free Full Text].
|
| 3.
|
Ashkenazi, A., and V. M. Dixit.
1998.
Death receptors: signaling and modulation.
Science
281:1305-1308[Abstract/Free Full Text].
|
| 4.
|
Astier, A.,
S. N. Manie,
S. F. Law,
T. Canty,
N. Hagheyeghi,
B. J. Druker,
R. Salgia,
E. A. Golemis, and A. S. Freedman.
1997.
Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in B cells. Possible relevance to neoplastic lymphohematopoietic cells.
Leuk. Lymphoma
28:65-72[Medline].
|
| 5.
|
Bannerman, D. D.,
M. Sathyamoorthy, and S. E. Goldblum.
1998.
Bacterial lipopolysaccharide disrupts endothelial monolayer integrity and survival signaling events through caspase cleavage of adherens junction proteins.
J. Biol. Chem.
273:35371-35380[Abstract/Free Full Text].
|
| 6.
|
Blaukat, A.,
I. Ivankovic-Dikic,
E. Gronroos,
F. Dolfi,
G. Tokiwa,
K. Vuori, and I. Dikic.
1999.
Adaptor proteins Grb2 and Crk couple Pyk2 with activation of specific mitogen-activated protein kinase cascades.
J. Biol. Chem.
274:14893-14901[Abstract/Free Full Text].
|
| 7.
|
Boudreau, N.,
C. J. Sympson,
Z. Werb, and M. J. Bissell.
1995.
Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix.
Science
267:891-893[Abstract/Free Full Text].
|
| 8.
|
Boulares, A. H.,
A. G. Yakovlev,
V. Ivanova,
B. A. Stoica,
G. Wang,
S. Iyer, and M. Smulson.
1999.
Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells.
J. Biol. Chem.
274:22932-22940[Abstract/Free Full Text].
|
| 9.
|
Brancolini, C.,
M. Benedetti, and C. Schneider.
1995.
Microfilament reorganization during apoptosis: the role of Gas2, a possible substrate for ICE-like proteases.
EMBO J.
14:5179-5190[Medline].
|
| 10.
|
Brancolini, C.,
D. Lazarevic,
J. Rodriguez, and C. Schneider.
1997.
Dismantling cell-cell contacts during apoptosis is coupled to a caspase-dependent proteolytic cleavage of beta-catenin.
J. Cell Biol.
139:759-771[Abstract/Free Full Text].
|
| 11.
|
Brinkman, A.,
S. van Der Flier,
E. M. Kok, and L. C. Dorssers.
2000.
BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
J. Natl. Cancer Inst.
92:112-120[Abstract/Free Full Text].
|
| 12.
|
Browne, S. J.,
M. MacFarlane,
G. M. Cohen, and C. Paraskeva.
1998.
The adenomatous polyposis coli protein and retinoblastoma protein are cleaved early in apoptosis and are potential substrates for caspases.
Cell Death Differ.
5:206-213[CrossRef][Medline].
|
| 13.
|
Burow, M. E.,
C. B. Weldon,
Y. Tang,
G. L. Navar,
S. Krajewski,
J. C. Reed,
T. G. Hammond,
S. Clejan, and B. S. Beckman.
1998.
Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants.
Cancer Res.
58:4940-4946[Abstract/Free Full Text].
|
| 14.
|
Cardone, M. H.,
G. S. Salvesen,
C. Widmann,
G. Johnson, and S. M. Frisch.
1997.
The regulation of anoikis: MEKK-1 activation requires cleavage by caspases.
Cell
90:315-323[CrossRef][Medline].
|
| 15.
|
Carmichael, J.,
W. G. DeGraff,
A. F. Gazdar,
J. D. Minna, and J. B. Mitchell.
1987.
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.
Cancer Res.
47:936-942[Abstract/Free Full Text].
|
| 16.
|
Cary, L. A.,
D. C. Han,
T. R. Polte,
S. K. Hanks, and J.-L. Guan.
1998.
Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration.
J. Cell Biol.
140:211-221[Abstract/Free Full Text].
|
| 17.
|
Casciola-Rosen, L.,
D. W. Nicholson,
T. Chong,
K. R. Rowan,
N. A. Thornberry,
D. K. Miller, and A. Rosen.
1996.
Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death.
J. Exp. Med.
183:1957-1964[Abstract/Free Full Text].
|
| 18.
|
Chaudhary, P. M.,
M. T. Eby,
A. Jasmin, and L. Hood.
1999.
Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs.
J. Biol. Chem.
274:19211-19219[Abstract/Free Full Text].
|
| 19.
|
Cheresh, D. A.,
J. Leng, and R. L. Klemke.
1999.
Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells.
J. Cell Biol.
146:1107-1116[Abstract/Free Full Text].
|
| 20.
|
Christerson, L. B.,
C. A. Vanderbilt, and M. H. Cobb.
1999.
MEKK1 interacts with alpha-actinin and localizes to stress fibers and focal adhesions.
Cell Motil. Cytoskel.
43:186-198[CrossRef][Medline].
|
| 21.
|
Derijard, B.,
M. Hibi,
I. H. Wu,
T. Barrett,
B. Su,
T. Deng,
M. Karin, and R. J. Davis.
1994.
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the cJun activation domain.
Cell
76:1025-1037[CrossRef][Medline].
|
| 22.
|
Dick, L. R.,
A. A. Cruikshank,
A. T. Destree,
L. Grenier,
T. A. McCormack,
F. D. Melandri,
S. L. Nunes,
V. J. Palombella,
L. A. Parent,
L. Plamondon, and R. L. Stein.
1997.
Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells.
J. Biol. Chem.
272:182-188[Abstract/Free Full Text].
|
| 23.
|
DiPietrantonio, A. M.,
T. Hsieh, and J. M. Wu.
1999.
Activation of caspase 3 in HL-60 cells exposed to hydrogen peroxide.
Biochem. Biophys. Res. Commun.
255:477-482[CrossRef][Medline].
|
| 24.
|
Dolfi, F.,
M. Garcia-Guzman,
M. Ojaniemi,
H. Nakamura,
M. Matsuda, and K. Vuori.
1998.
The adaptor protein Crk connects multiple cellular stimuli to the JNK signaling pathway.
Proc. Natl. Acad. Sci. USA
95:15394-15399[Abstract/Free Full Text].
|
| 25.
|
Evan, G. I.,
L. Brown,
M. Whyte, and E. Harrington.
1995.
Apoptosis and the cell cycle.
Curr. Opin. Cell Biol.
7:825-834[CrossRef][Medline].
|
| 26.
|
Frisch, S. M., and H. Francis.
1994.
Disruption of epithelial cell-matrix interactions induces apoptosis.
J. Cell Biol.
124:619-626[Abstract/Free Full Text].
|
| 27.
|
Frisch, S. M.,
K. Vuori,
E. Ruoslahti, and P.-Y. Chan-Hui.
1996.
Control of adhesion-dependent cell survival by focal adhesion kinase.
J. Cell Biol.
134:793-799[Abstract/Free Full Text].
|
| 28.
|
Gervais, F. G.,
N. A. Thornberry,
S. C. Ruffolo,
D. W. Nicholson, and S. Roy.
1998.
Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide.
J. Biol. Chem.
273:17102-17108[Abstract/Free Full Text].
|
| 29.
|
Gervais, J. L.,
P. Seth, and H. Zhang.
1998.
Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis.
J. Biol. Chem.
273:19207-19212[Abstract/Free Full Text].
|
| 30.
|
Ghayur, T.,
S. Banerjee,
M. Hugunin,
D. Butler,
L. Herzog,
A. Carter,
L. Quintal,
L. Sekut,
R. Talanian,
M. Paskind,
W. Wong,
R. Kamen,
D. Tracey, and H. Allen.
1997.
Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production.
Nature
386:619-623[CrossRef][Medline].
|
| 31.
|
Goldberg, Y. P.,
D. W. Nicholson,
D. M. Rasper,
M. A. Kalchman,
H. B. Koide,
R. K. Graham,
M. Bromm,
P. Kazemi-Esfarjani,
N. A. Thornberry,
J. P. Vaillancourt, and M. R. Hayden.
1996.
Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract.
Nat. Genet.
13:442-449[CrossRef][Medline].
|
| 32.
|
Green, D. R., and J. C. Reed.
1998.
Mitochondria and apoptosis.
Science
281:1309-1312[Abstract/Free Full Text].
|
| 33.
|
Gu, Z.,
C. Flemington,
T. Chittenden, and G. P. Zambetti.
2000.
ei24, a p53 response gene involved in growth suppression and apoptosis.
Mol. Cell. Biol.
20:233-241[Abstract/Free Full Text].
|
| 34.
|
Han, Z.,
N. Malik,
T. Carter,
W. H. Reeves,
J. H. Wyche, and E. A. Hendrickson.
1996.
DNA-dependent protein kinase is a target for a CPP32-like apoptotic protease.
J. Biol. Chem.
271:25035-25040[Abstract/Free Full Text].
|
| 35.
|
Hungerford, J. E.,
M. T. Compton,
M. L. Matter,
B. G. Hoffstrom, and C. A. Otey.
1996.
Inhibition of pp125FAK in cultured fibroblasts results in apoptosis.
J. Cell Biol.
135:1383-1390[Abstract/Free Full Text].
|
| 36.
|
Ikebe, T.,
H. Takeuchi,
E. Jimi,
M. Beppu,
M. Shinohara, and K. Shirasuna.
1998.
Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma.
Int. J. Cancer
77:578-585[CrossRef][Medline].
|
| 37.
|
Ip, Y. T., and R. J. Davis.
1998.
Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development.
Curr. Opin. Cell Biol.
10:205-219[CrossRef][Medline].
|
| 38.
|
Ishino, M.,
T. Ohba,
H. Sasaki, and T. Sasaki.
1995.
Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn.
Oncogene
11:2331-2338[Medline].
|
| 39.
|
Janicke, R. U.,
M. L. Sprengart,
M. R. Wati, and A. G. Porter.
1998.
Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis.
J. Biol. Chem.
273:9357-9360[Abstract/Free Full Text].
|
| 40.
|
Janicke, R. U.,
P. A. Walker,
X. Y. Lin, and A. G. Porter.
1996.
Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis.
EMBO J.
15:6969-6978[Medline].
|
| 41.
|
Kerr, J. F.,
A. H. Wyllie, and A. R. Currie.
1972.
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.
Br. J. Cancer
26:239-257[Medline].
|
| 42.
|
King, K. L., and J. A. Cidlowski.
1995.
Cell cycle and apoptosis: common pathways to life and death.
J. Cell. Biochem.
58:175-180[CrossRef][Medline].
|
| 43.
|
Klemke, R. L.,
J. Leng,
R. Molander,
P. C. Brooks,
K. Vuori, and D. A. Cheresh.
1998.
CAS/Crk coupling serves as a "molecular switch" for induction of cell migration.
J. Cell Biol.
140:961-972[Abstract/Free Full Text].
|
| 44.
|
Kothakota, S.,
T. Azuma,
C. Reinhard,
A. Klippel,
J. Tang,
K. Chu,
T. J. McGarry,
M. W. Kirschner,
K. Koths,
D. J. Kwiatkowski, and L. T. Williams.
1997.
Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis.
Science
278:294-298[Abstract/Free Full Text].
|
| 45.
|
Law, S. F.,
J. Estojak,
B. Wang,
T. Mysliwiec,
G. D. Kruh, and E. A. Golemis.
1996.
Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae.
Mol. Cell. Biol.
16:3327-3337[Abstract].
|
| 46.
|
Law, S. F.,
Y.-Z. Zhang,
S. Fashena,
G. Toby,
J. Estojak, and E. A. Golemis.
1999.
Dimerization of the docking/adaptor protein HEF1 via a carboxy-terminal helix-loop-helix domain.
Exp. Cell Res.
252:224-235[CrossRef][Medline].
|
| 47.
|
Law, S. F.,
Y.-Z. Zhang,
A. Klein-Szanto, and E. A. Golemis.
1998.
Cell-cycle regulated processing of HEF1 to multiple protein forms differentially targeted to multiple compartments.
Mol. Cell. Biol.
18:3540-3551[Abstract/Free Full Text].
|
| 48.
|
Lazebnik, Y. A.,
S. Cole,
C. A. Cooke,
W. G. Nelson, and W. C. Earnshaw.
1993.
Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis.
J. Cell Biol.
123:7-22[Abstract/Free Full Text].
|
| 49.
|
Lazebnik, Y. A.,
S. H. Kaufmann,
S. Desnoyers,
G. G. Poirier, and W. C. Earnshaw.
1994.
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE.
Nature
371:346-347[CrossRef][Medline].
|
| 50.
|
Lazebnik, Y. A.,
A. Takahashi,
R. D. Moir,
R. D. Goldman,
G. G. Poirier,
S. H. Kaufmann, and W. C. Earnshaw.
1995.
Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution.
Proc. Natl. Acad. Sci. USA
92:9042-9046[Abstract/Free Full Text].
|
| 51.
|
Lee, N.,
H. MacDonald,
C. Reinhard,
R. Halenbeck,
A. Roulston,
T. Shi, and L. T. Williams.
1997.
Activation of hPAK65 by caspase cleavage induces some of the morphological and biochemical changes of apoptosis.
Proc. Natl. Acad. Sci. USA
94:13642-13647[Abstract/Free Full Text].
|
| 52.
|
Lenczowski, J. M.,
L. Dominguez,
A. M. Eder,
L. B. King,
C. M. Zacharchuk, and J. D. Ashwell.
1997.
Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis.
Mol. Cell. Biol.
17:170-181[Abstract].
|
| 53.
|
Li, F.,
G. Ambrosini,
E. Y. Chu,
J. Plescia,
S. Tognin,
P. C. Marchisio, and D. C. Altieri.
1998.
Control of apoptosis and mitotic spindle checkpoint by survivin.
Nature
396:580-584[CrossRef][Medline].
|
| 54.
|
Liu, Z. G.,
H. Hsu,
D. V. Goeddel, and M. Karin.
1996.
Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death.
Cell
87:565-576[CrossRef][Medline].
|
| 55.
|
Los, M.,
S. Wesselborg, and K. Schulze-Osthoff.
1999.
The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice.
Immunity
10:629-639[CrossRef][Medline].
|
| 56.
|
Lu, Y.,
J. Brush, and T. Stewart.
1999.
NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase/stress-activated protein kinase signaling pathway.
J. Biol. Chem.
274:10047-10052[Abstract/Free Full Text].
|
| 57.
|
Manie, S. N.,
A. R. P. Beck,
A. Astier,
S. F. Law,
T. Canty,
H. Hirai,
B. J. Druker,
H. Avraham,
N. Haghayegi,
M. Sattler,
R. Salgia,
J. D. Griffin,
E. A. Golemis, and A. S. Freedman.
1997.
Involvement of p130Cas and p105HEF1, a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells.
J. Biol. Chem.
272:4230-4236[Abstract/Free Full Text].
|
| 58.
|
Martin, S. J.,
G. A. O'Brien,
W. K. Nishioka,
A. J. McGahon,
A. Mahboubi,
T. C. Saido, and D. R. Green.
1995.
Proteolysis of fodrin (non-erythroid spectrin) during apoptosis.
J. Biol. Chem.
270:6425-6428[Abstract/Free Full Text].
|
| 59.
|
Minegishi, M.,
K. Tachibana,
T. Sato,
S. Iwata,
Y. Nojima, and C. Morimoto.
1996.
Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta-1 integrin-mediated signaling in lymphocytes.
J. Exp. Med.
184:1365-1375[Abstract/Free Full Text].
|
| 60.
|
Miossec, C.,
V. Dutilleul,
F. Fassy, and A. Diu-Hercend.
1997.
Evidence for CPP32 activation in the absence of apoptosis during T lymphocyte stimulation.
J. Biol. Chem.
272:13459-13462[Abstract/Free Full Text].
|
| 61.
|
Na, S.,
T. H. Chuang,
A. Cunningham,
T. G. Turi,
J. H. Hanke,
G. M. Bokoch, and D. E. Danley.
1996.
D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis.
J. Biol. Chem.
271:11209-11213[Abstract/Free Full Text].
|
| 62.
|
Nagata, K.-I.,
A. Puls,
C. Futter,
P. Aspenstrom,
E. Schaefer,
T. Nakata,
N. Hirokawa, and A. Hall.
1998.
The MAP kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3.
EMBO J.
17:149-158[CrossRef][Medline].
|
| 63.
|
Nojima, Y.,
N. Morino,
T. Mimura,
K. Hamasaki,
H. Furuya,
R. Sakai,
T. Sato,
K. Tachibana,
C. Morimoto,
Y. Yazaki, and H. Hirai.
1995.
Integrin-mediated cell adhesion promotes tyrosine phosphorylation of p130Cas, a Src homology 3-containing molecule having multiple Src homology 2-binding motifs.
J. Biol. Chem.
270:15398-15402[Abstract/Free Full Text].
|
| 64.
|
Ohashi, Y.,
S. Iwata,
K. Kamiguchi, and C. Morimoto.
1999.
Tyrosine phosphorylation of Crk-associated substrate lymphocyte-type is a critical element in TCR- and beta1 integrin-induced T lymphocyte migration.
J. Immunol.
163:3727-3734[Abstract/Free Full Text].
|
| 65.
|
Ohashi, Y.,
K. Tachibana,
K. Kamiguchi,
H. Fujita, and C. Morimoto.
1998.
T cell receptor-mediated tyrosine phosphorylation of Cas-L, a 105-kDa Crk-associated substrate-related protein, and its association of Crk and C3G.
J. Biol. Chem.
273:6446-6451[Abstract/Free Full Text].
|
| 66.
|
Ohba, T.,
M. Ishino,
H. Aoto, and T. Sasaki.
1998.
Dot far-Western blot analysis of relative binding affinities of the src homology 3 domains of efs and its related proteins.
Anal. Biochem.
262:185-192[CrossRef][Medline].
|
| 67.
|
O'Neill, G. M.,
S. J. Fashena, and E. A. Golemis.
2000.
Integrin signaling: a new Cas(t) of characters enters the stage.
Trends Cell Biol.
10:111-119[CrossRef][Medline].
|
| 68.
|
Orlowski, R. Z.
1999.
The role of the ubiquitin-proteasome pathway in apoptosis.
Cell Death Differ.
6:303-313[CrossRef][Medline].
|
| 69.
|
Pettmann, B., and C. E. Henderson.
1998.
Neuronal cell death.
Neuron
20:633-647[CrossRef][Medline].
|
| 70.
|
Rudel, T., and G. M. Bokoch.
1997.
Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2.
Science
276:1571-1574[Abstract/Free Full Text].
|
| 71.
|
Sakai, R.,
A. Iwamatsu,
N. Hirano,
S. Ogawa,
T. Tanaka,
H. Mano,
Y. Yazaki, and H. Hirai.
1994.
A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner.
EMBO J.
13:3748-3756[Medline].
|
| 72.
|
Sakakibara, A., and S. Hattori.
2000.
Chat, a Cas/HEF1-associated adaptor protein that integrates multiple signaling pathways.
J. Biol. Chem.
275:6404-6410[Abstract/Free Full Text].
|
| 73.
|
Sattler, M.,
R. Salgia,
G. Shrikhande,
S. Verma,
N. Uemura,
S. F. Law,
E. A. Golemis, and J. D. Griffin.
1997.
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120CBL and p110HEF1.
J. Biol. Chem.
272:14320-14326[Abstract/Free Full Text].
|
| 74.
|
Scaffidi, C.,
S. Kirchhoff,
P. H. Krammer, and M. E. Peter.
1999.
Apoptosis signaling in lymphocytes.
Curr. Opin. Immunol.
11:277-285[CrossRef][Medline].
|
| 75.
|
Simbulan-Rosenthal, C. M.,
D. S. Rosenthal,
S. Iyer,
A. H. Boulares, and M. E. Smulson.
1998.
Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis.
J. Biol. Chem.
273:13703-13712[Abstract/Free Full Text].
|
| 76.
|
Song, Q.,
S. P. Lees-Miller,
S. Kumar,
Z. Zhang,
D. W. Chan,
G. C. Smith,
S. P. Jackson,
E. S. Alnemri,
G. Litwack,
K. K. Khanna, and M. F. Lavin.
1996.
DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis.
EMBO J.
15:3238-3246[Medline].
|
| 77.
|
Tachibana, K.,
T. Urano,
H. Fujita,
Y. Ohashi,
K. Kamiguchi,
S. Iwata,
H. Hirai, and C. Morimoto.
1997.
Tyrosine phosphorylation of crk-associated substrates by focal adhesion kinase. A putative mechanism for the integrin-mediated tyrosine phosphorylation of crk-associated substrates.
J. Biol. Chem.
272:29083-29090[Abstract/Free Full Text].
|
| 78.
|
Takahashi, A.,
E. S. Alnemri,
Y. A. Lazebnik,
T. Fernandes-Alnemri,
G. Litwack,
R. D. Moir,
R. D. Goldman,
G. Poirier,
S. H. Kaufmann, and W. C. Earnshaw.
1996.
Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis.
Proc. Natl. Acad. Sci. USA
93:8395-8400[Abstract/Free Full Text].
|
| 79.
|
Tewari, M.,
D. R. Beidler, and V. M. Dixit.
1995.
CrmA-inhibitable cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein during Fas- and tumor necrosis factor-induced apoptosis.
J. Biol. Chem.
270:18738-18741[Abstract/Free Full Text].
|
| 80.
|
Thornberry, N. A., and Y. Lazebnik.
1998.
Caspases: enemies within.
Science
281:1312-1316[Abstract/Free Full Text].
|
| 81.
|
Tsubata, T.,
J. Wu, and T. Honjo.
1993.
B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40.
Nature
364:645-648[CrossRef][Medline].
|
| 82.
|
van Agthoven, T.,
T. L. van Agthoven,
A. Dekker,
P. J. van der Spek,
L. Vreede, and L. C. Dorssers.
1998.
Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.
EMBO J.
17:2799-2808[CrossRef][Medline].
|
| 83.
|
van der Flier, S.,
A. Brinkman,
M. P. Look,
E. M. Kok,
M. E. Meijer-Van Gelder,
J. G. Klijn,
L. C. Dorssers, and J. A. Foekens.
2000.
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
J. Natl. Cancer Inst.
92:120-127[Abstract/Free Full Text].
|
| 84.
|
Vuori, K., and E. Ruoslahti.
1995.
Tyrosine phosphorylation of p130Cas and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix.
J. Biol. Chem.
270:22259-22262[Abstract/Free Full Text].
|
| 85.
|
Wang, X.,
N. G. Zelenski,
J. Yang,
J. Sakai,
M. S. Brown, and J. L. Goldstein.
1996.
Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis.
EMBO J.
15:1012-1020[Medline].
|
| 86.
|
Watanabe, Y., and T. Akaike.
1999.
Possible involvement of caspase-like family in maintenance of cytoskeleton integrity.
J. Cell. Physiol.
179:45-51[CrossRef][Medline].
|
| 87.
|
Wen, L. P.,
J. A. Fahrni,
S. Troie,
J. L. Guan,
K. Orth, and G. D. Rosen.
1997.
Cleavage of focal adhesion kinase by caspases during apoptosis.
J. Biol. Chem.
272:26056-26061[Abstract/Free Full Text].
|
Molecular and Cellular Biology, July 2000, p. 5184-5195, Vol. 20, No. 14
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ta, H. Q., Thomas, K. S., Schrecengost, R. S., Bouton, A. H.
(2008). A Novel Association between p130Cas and Resistance to the Chemotherapeutic Drug Adriamycin in Human Breast Cancer Cells. Cancer Res.
68: 8796-8804
[Abstract]
[Full Text]
-
Singh, M. K., Dadke, D., Nicolas, E., Serebriiskii, I. G., Apostolou, S., Canutescu, A., Egleston, B. L., Golemis, E. A.
(2008). A Novel Cas Family Member, HEPL, Regulates FAK and Cell Spreading. Mol. Biol. Cell
19: 1627-1636
[Abstract]
[Full Text]
-
Martin-Rendon, E., Hale, S. J.M., Ryan, D., Baban, D., Forde, S. P., Roubelakis, M., Sweeney, D., Moukayed, M., Harris, A. L., Davies, K., Watt, S. M.
(2007). Transcriptional Profiling of Human Cord Blood CD133+ and Cultured Bone Marrow Mesenchymal Stem Cells in Response to Hypoxia. Stem Cells
25: 1003-1012
[Abstract]
[Full Text]
-
Dadke, D., Jarnik, M., Pugacheva, E. N., Singh, M. K., Golemis, E. A.
(2006). Deregulation of HEF1 Impairs M-Phase Progression by Disrupting the RhoA Activation Cycle. Mol. Biol. Cell
17: 1204-1217
[Abstract]
[Full Text]
-
Zheng, M., McKeown-Longo, P. J.
(2006). Cell adhesion regulates Ser/Thr phosphorylation and proteasomal degradation of HEF1. J. Cell Sci.
119: 96-103
[Abstract]
[Full Text]
-
Chang, J., Gudima, S. O., Tarn, C., Nie, X., Taylor, J. M.
(2005). Development of a Novel System To Study Hepatitis Delta Virus Genome Replication. J. Virol.
79: 8182-8188
[Abstract]
[Full Text]
-
Liu, F., Dowling, M., Yang, X.-J., Kao, G. D.
(2004). Caspase-mediated Specific Cleavage of Human Histone Deacetylase 4. J. Biol. Chem.
279: 34537-34546
[Abstract]
[Full Text]
-
Feng, L., Guedes, S., Wang, T.
(2004). Atrophin-1-interacting Protein 4/Human Itch Is a Ubiquitin E3 Ligase for Human Enhancer of Filamentation 1 in Transforming Growth Factor-{beta} Signaling Pathways. J. Biol. Chem.
279: 29681-29690
[Abstract]
[Full Text]
-
Einarson, M. B., Cukierman, E., Compton, D. A., Golemis, E. A.
(2004). Human Enhancer of Invasion-Cluster, a Coiled-Coil Protein Required for Passage through Mitosis. Mol. Cell. Biol.
24: 3957-3971
[Abstract]
[Full Text]
-
Kim, W., Kook, S., Kim, D. J., Teodorof, C., Song, W. K.
(2004). The 31-kDa Caspase-generated Cleavage Product of p130cas Functions as a Transcriptional Repressor of E2A in Apoptotic Cells. J. Biol. Chem.
279: 8333-8342
[Abstract]
[Full Text]
-
Goldberg, G. S., Alexander, D. B., Pellicena, P., Zhang, Z.-Y., Tsuda, H., Miller, W. T.
(2003). Src Phosphorylates Cas on Tyrosine 253 to Promote Migration of Transformed Cells. J. Biol. Chem.
278: 46533-46540
[Abstract]
[Full Text]
-
Dho, S. H., Kwon, K.-S.
(2003). The Ret Finger Protein Induces Apoptosis via Its RING Finger-B Box-Coiled-coil Motif. J. Biol. Chem.
278: 31902-31908
[Abstract]
[Full Text]
-
Toby, G. G., Gherraby, W., Coleman, T. R., Golemis, E. A.
(2003). A Novel RING Finger Protein, Human Enhancer of Invasion 10, Alters Mitotic Progression through Regulation of Cyclin B Levels. Mol. Cell. Biol.
23: 2109-2122
[Abstract]
[Full Text]
-
Cai, D., Felekkis, K. N., Near, R. I., O'Neill, G. M., van Seventer, J. M., Golemis, E. A., Lerner, A.
(2003). The GDP Exchange Factor AND-34 Is Expressed in B Cells, Associates With HEF1, and Activates Cdc42. J. Immunol.
170: 969-978
[Abstract]
[Full Text]
-
Zheng, M., McKeown-Longo, P. J.
(2002). Regulation of HEF1 Expression and Phosphorylation by TGF-beta 1 and Cell Adhesion. J. Biol. Chem.
277: 39599-39608
[Abstract]
[Full Text]
-
Stupack, D. G., Cheresh, D. A.
(2002). Get a ligand, get a life: integrins, signaling and cell survival. J. Cell Sci.
115: 3729-3738
[Abstract]
[Full Text]
-
Fashena, S. J., Einarson, M. B., O'Neill, G. M., Patriotis, C., Golemis, E. A.
(2002). Dissection of HEF1-dependent functions in motility and transcriptional regulation. J. Cell Sci.
115: 99-111
[Abstract]
[Full Text]
-
O'Neill, G. M., Golemis, E. A.
(2001). Proteolysis of the Docking Protein HEF1 and Implications for Focal Adhesion Dynamics. Mol. Cell. Biol.
21: 5094-5108
[Abstract]
[Full Text]
-
Prasad, N., Topping, R. S., Decker, S. J.
(2001). SH2-Containing Inositol 5'-Phosphatase SHIP2 Associates with the p130Cas Adapter Protein and Regulates Cellular Adhesion and Spreading. Mol. Cell. Biol.
21: 1416-1428
[Abstract]
[Full Text]